Pullach, Germany

Maximiliane Koenig

USPTO Granted Patents = 7 

 

 

Average Co-Inventor Count = 7.4

ph-index = 2

Forward Citations = 35(Granted Patents)


Location History:

  • Munich, DE (2017)
  • Penzberg, DE (2021)
  • Pullach, DE (2018 - 2022)
  • Diesenhofen, DE (2023)

Company Filing History:


Years Active: 2017-2024

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Maximiliane Koenig: Innovator in Antibody Development

Introduction

Maximiliane Koenig is a prominent inventor based in Pullach, Germany. She has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic applications. With a total of seven patents to her name, her work has the potential to impact the treatment of various diseases.

Latest Patents

One of her latest patents focuses on antibodies that bind to STEAP-1. This invention includes bispecific antigen binding molecules designed for activating T cells. Additionally, the patent covers polynucleotides encoding such antibodies, as well as vectors and host cells that comprise these polynucleotides. The invention also outlines methods for producing the antibodies and their applications in disease treatment.

Career Highlights

Throughout her career, Maximiliane has worked with notable companies in the biotechnology sector, including Hoffmann-La Roche Inc. and Roche Glycart AG. Her experience in these organizations has allowed her to refine her expertise in antibody development and therapeutic applications.

Collaborations

Maximiliane has collaborated with esteemed colleagues such as Ekkehard Moessner and Joerg Moelleken. These partnerships have contributed to her innovative research and the advancement of her projects.

Conclusion

Maximiliane Koenig is a trailblazer in the field of antibody research, with a strong portfolio of patents that reflect her dedication to advancing medical science. Her work continues to pave the way for new therapeutic strategies in treating diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…